By Bruce Buckley
On July 1, 2018, the U.S. Pharmacopeial Convention (USP) General Chapter <800> will go into effect, including the required use of a closed system drug-transfer device (CSTD) for cytotoxic agents. In the following Q&A interview, James Jorgenson, MS, RPh, FASHP, the CEO of Visante Inc., tells why a CSTD is so vital to the safe preparation and administration of hazardous drugs and why pharmacy and nursing need to approach the selection of an appropriate system with the